Skip to main content
SpringerLink
Log in

Periwinkle Alkaloids I: Vinblastine and Vindesine

  • Chapter
Cancer Chemotherapy by Infusion

Abstract

Vinblastine (vlb) and vindesine (vds) are vinca alkaloids, a class of drugs in widespread clinical use. VDS (desacetyl vinblastine amide sulfate) is a semisynthetic derivative of VLB. The mechanism of action of these drugs has been extensively reviewed elsewhere.1 These drugs have a very high affinity for tubulin and inhibit its polymerization. This leads to mitotic arrest and subsequent cell death. The vinca alkaloids are most active against premitotic cells and thus are cell cycle phase-specific agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bender RA. Vinca alkaloids and epipodophyllotoxins. In: Pinedo HM, ed. Cancer Chemotherapy 1979. New York: Elsevier, 1979; 93–106.

    Google Scholar 

  2. Root MA, Gerzon K, Dyke RW. A radioimmunoassay for vinblastine and vincristine. In: Federation of analytical chemistry and spectroscopy societies, abstract 183 (1975) 1254.

    Google Scholar 

  3. Sethi VS, Burton SS, Jackson DV. A sensitive radioimmunoassay for vincristine and vinblastine. Cancer Chemother Pharmacol 1980; 4: 183–87.

    Article  PubMed  CAS  Google Scholar 

  4. Rahmani R, Barbet J, Cano JP. A 125I-radiolabelled probe for vinblastine and vindestine radioimmunoassays: applications to measurements of vindesine plasma levels in man after intravenous injections and long-term infusions. Clin Chim Acta 1983; 129: 51–69.

    Article  Google Scholar 

  5. Ratain MJ, Holt J A, Sinkule J A, Vogelzang NJ. Modificaiton of the vinca alkaloid radioimmunoassay for improved sensitivity: application for measurement of serum concentrations during prolonged continuous vinblastine infusion (submitted for publication).

    Google Scholar 

  6. Owellen RJ, Root MA, Hains FO. Pharmacokinetics of vindesine and vincristine in humans. Cancer Res 1977; 37: 2603–07.

    PubMed  CAS  Google Scholar 

  7. Owellen RJ, Hartke CA, Harris FO. Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res 1977; 37: 2597–2602.

    PubMed  CAS  Google Scholar 

  8. Nelson RL, Dyke RW, Root MA. Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treat Rev 1980; 7 (suppl): 17–24.

    Article  PubMed  Google Scholar 

  9. Jackson DV, Sethi VS, Long TR, Mass HB, Spurr CL. Pharmacokinetics of vindesine bolus and infusion. Cancer Chemother Pharmacol 1984; 13: 114–19.

    PubMed  Google Scholar 

  10. Rahmani R, Martin M, Faure R, Cano JP, Barbet J. Clinical pharmacokinetics of vindesine: repeated treatments by intravenous bolus injections. Eur J Cancer Clin Oncol 1984; 20: 1409–17.

    Article  PubMed  CAS  Google Scholar 

  11. Ohnuma T, Norton L, Andrejczuk A, Holland JF. Pharmacokinetics of vindesine given as an intravenous bolus and 24-hour infusion in humans. Cancer Res 1985; 454: 464–69.

    Google Scholar 

  12. Ratain MJ, Vogelzang NJ, Sinkule JA, Holt J A. Phase 1 pharmacokinetic (PK) and toxicity study of prolonged continuous infusion vinblastine (CIV) using infusion (INF) pumps. Proc Am Assoc Cane Res 1985; 26: 162.

    Google Scholar 

  13. Hande K, Gay J, Gober J, Greco FA. Toxicity and pharmacology of bolus vindesine injection and prolonged vindesine infusion. Cancer Treat Rev 1980; 7 (suppl): 25–30.

    Article  PubMed  Google Scholar 

  14. Jackson DV, Castle MC, Bender RA. Biliary excretion of (3H)-vincristine in man. Clîn Pharmacol Ther 1978; 24: 101–07.

    PubMed  Google Scholar 

  15. Dyke RW, Nelson RL. Phase 1 anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate). Cancer Treat Rev 1977; 4: 135–42.

    Article  PubMed  CAS  Google Scholar 

  16. Valdivieso M, Richman S, Burgess MA, Bodey GP, Freireich EJ. Initial clinical studies of vindesine. Cancer Treat Rep 1981; 65: 873–75.

    PubMed  CAS  Google Scholar 

  17. Frei E, Franzino A, Shnider BI, et al. Clinical studies of vinblastine. Cancer Chemother Rep 1961; 12: 125–29.

    PubMed  Google Scholar 

  18. Bruce WR, Meeker BE, Powers WE, Valeriote FA. Comparison of the dose -and time-survival curves for normal hematopoietic and lymphoma colony-forming cells exposed to vinblastine, vincristine, arabinosylcytosine, and amethopterin. J Natl Cancer Inst 1969; 42: 1015–23.

    PubMed  CAS  Google Scholar 

  19. Jusko WJ. A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents. J Pharma- cokin Biopharm 1973; 1: 175–200.

    Article  CAS  Google Scholar 

  20. Hill BT, Whelan RDH. Comparative effects of vincristine and vindesine on cell cycle kinetics in vitro. Cancer Treat Rev 1980; 7 (suppl): 5–15.

    Article  PubMed  Google Scholar 

  21. Ludwig R, Alberts DS, Miller TP, Salmon SE. Evaluation of anticancer drug schedule dependency using an in vitro human tumor clonogenic assay. Cancer Chemother Pharmacol 1984; 12: 135–41.

    PubMed  CAS  Google Scholar 

  22. Matsushima Y, Kanzawa F, Hoshi A, et al. Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol 1985; 14: 104–07.

    Article  PubMed  CAS  Google Scholar 

  23. Lengsfeld AM, Dietrich J, Schultz-Maures B. Accumulation and release of vinblastine and vincristine by Hela cells: light microscopic, cinematographic, and biochemical study. Cancer Res 1982; 42: 3798–3805.

    PubMed  CAS  Google Scholar 

  24. Ferguson PJ, Phillips JR, Seiner M, Cass CE. Differential activity of vincristine and vinblastine against cultured cells. Cancer Res 1984; 44: 3307–12.

    PubMed  CAS  Google Scholar 

  25. Owellen RJ, Donigan DW, Hartke CA, Harris FO. Correlation of biologic data with physicochemical properties among the vinca alkaloids and their congeners. Biochem Pharmacol 1977; 26: 1213–19.

    Article  PubMed  CAS  Google Scholar 

  26. Ferguson PJ, Cass CE. The basis of differential toxicity of vincristine and vinblastine against HL-60/cl cells is rapid release of vinblastine. Proc Am Assoc Canc Res 1985; 26: 236.

    Google Scholar 

  27. Gout PW, Noble RL, Bruchorsky N, Beer CT. Vinblastine and vincristine-growth-inhibitory effects correlate with their retention by cultured Nb 2 node lymphoma cells. Int J Cancer 1984; 34: 245–48.

    Article  PubMed  CAS  Google Scholar 

  28. Yap HY, Blumenschein GR, Keating MJ, Hortobagyi GN, Tashima CK, Loo TL. Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep 1980; 64: 279–83.

    PubMed  CAS  Google Scholar 

  29. Young J A, Howell SB, Green MR. Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine. Cancer Chemother Pharmacol 1984; 12: 43–45.

    Article  PubMed  CAS  Google Scholar 

  30. Zeffren J, Yagoda A, Kelsen D, Will R. Phase 1–2 trial of a 5-day continuous infusion of vinblastine sulfate. Anticancer Res 1984; 4: 411–14.

    PubMed  CAS  Google Scholar 

  31. Lokich JJ, Zipoli TE, Perri J, Bothe A. Protracted vinblastine infusion. Phase 1–2 study in malignant melanoma and other tumors. Am J Clin Oncol 1984; 7: 551–53.

    Article  PubMed  CAS  Google Scholar 

  32. Lokich J, Bothe A, Fine N, Perri J. The delivery of cancer chemotherapy by constant venous infusion. Ambulatory management of venous access and portable pump. Cancer 1982; 50: 2731–35.

    Article  PubMed  CAS  Google Scholar 

  33. Ensminger W, Niederhuber J, Dakhil S, Thrail J, Wheeler R. Totally implanted drug delivery system for hepatic arterial chemotherapy. Cancer Treat Rep 1981; 65: 393–400.

    PubMed  CAS  Google Scholar 

  34. Vogelzang NJ, Ruane MJ, Demeester TR. Phase 1 trial of implanted battery-powered, programmable drug delivery system for continuous doxorubicin administration. J Clin Oncol 1985; 3: 407–14.

    PubMed  CAS  Google Scholar 

  35. Lu K, Yap HY, Loo TL. Clinical pharmacokinetics of vinblastine by continuous intravenous infusion. Cancer Res 1983; 43: 1405–08.

    PubMed  CAS  Google Scholar 

  36. Chacon RD, Kotliar ML, Cavarva G, et al. Phase 2 study with vinblastine continuous infusion (Vb CI). Proc Am Soc Clin Oncol 1982; 1: 33.

    Google Scholar 

  37. Tannock I, Erlichman C, Perrault D, Quirt I, King M. Failure of 5-day vinblastine in the treatment of patients with advanced refractory breast cancer. Cancer Treat Rep 1982; 66: 1783–84.

    PubMed  CAS  Google Scholar 

  38. Ingle JN, Ahmann DL, Gersther JG, Green SJ, O’Connell MJ, Kuols LK. Evaluation of vinblastine administered by 5-day continuous infusion in women with advanced breast cancer. Cancer Treat Rep 1984; 68: 803–04.

    PubMed  CAS  Google Scholar 

  39. Shah MK, Greech RH, Catalono RB, St. Mariek. Phase 2 study of vinblastine infusion in the treatment of refractory advanced breast cancer. Proc Am Soc Clin Oncol 1982; 1: 73.

    Google Scholar 

  40. Yau JC, Yap YY, Buzdar AU, Hortobagyi GN, Body GP, Blumenschein GR. A comparative randomized trial of vinca alkaloids in patients with metastatic breast cancer. Cancer 1985; 55: 337–40.

    Article  PubMed  CAS  Google Scholar 

  41. Paschold EH, Jackson DV. Spurr CL, et al. Continuous infusion of vincristine (VCR) and vinblastine (VLB) in refractory lymphoma: a phase 2 study. Proc Am Soc Clin Oncol 1982; 1: 159.

    Google Scholar 

  42. Kavanagh J J, Wharton JT, Rutledge FN. Continuous-infusion vinblastine for treatment of refractory epithelial carcinoma of the ovary: a phase 2 trial. Cancer Treat Rep 1984; 68: 1417–18.

    PubMed  CAS  Google Scholar 

  43. Kuebler JP, Hogan TF, Trump DL, Bryan GT. Phase 2 study of continuous 5-day vinblastine infusion in renal adenocarcinoma. Cancer Treat Rep 1984; 68: 925–26.

    PubMed  CAS  Google Scholar 

  44. Yap BS, Benjamin RS, Plager C, Burgess MA, Papadoupolos N, Bodey GP. A randomized study of continuous infusion vindesine versus vinblastine in adults with refractory sarcomas. Am J Clin Oncol 1983; 6: 235–38.

    Article  PubMed  CAS  Google Scholar 

  45. Yap HY, Blumenschein GR, Hortobagyi GN, Buzdar AU, Schell FC, Bodey GP. Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer. Am J Clin Oncol 1982; 5: 511–14.

    PubMed  CAS  Google Scholar 

  46. Tannir N, Yap HY, Hortobagyi GH, Hug V, Buzdar AU, Blumenschein GR. Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone. Cancer Treat Rep 1984; 68: 1039–41.

    PubMed  CAS  Google Scholar 

  47. Logothetis CJ, Samuels ML, Selig D, Swanson D, Johnson DE, von Eschenbach AC. Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. J Clin Oncol 1985; 3: 326–35.

    PubMed  CAS  Google Scholar 

  48. Chong C, Logothetis C, Fristche H, Gietner A, Savaraj N, Samuels M. Peak vinblastine concentration as a monitor of nonhematologic toxicity in patients with testicular cancer. Proc Am Assoc Cane Res 1985; 26: 173.

    Google Scholar 

  49. Ohnuma T, Greenspan EM, Holland JF. Initial clinical study with vindesine: tolerance to weekly I.V. bolus and 24-hour infusion. Cancer Treat Rep 1980; 64: 25–30.

    PubMed  CAS  Google Scholar 

  50. Gilby ED. A comparison of vindesine administration by bolus injection and by 24-hour infusion. Cancer Treat Rev 1980; 7 (suppl): 47–51.

    Article  PubMed  Google Scholar 

  51. Yap HY, Blumenschein GR, Bodey GP, Hortobagyi GN, Buzdar AU, DiStefano A. Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion. Cancer Treat Rep 1981; 65: 775–79.

    PubMed  CAS  Google Scholar 

  52. Bodey GP, Yap HY, Blumenschein GR, Savaraj N, Loo TL. Continuous infusion of vindesine in breast carcinoma. Clinical and pharmacology studies. In: Brade W, Nagel GA, Seeber S, eds. Proc International Vinca Alkaloid Symposium–Vindesine, Basel: S. Karger, 1981; 203–11.

    Google Scholar 

  53. Hansen PV, Brincker H. Vindesine in the treatment of metastatic breast cancer. Eur J Cancer Clin Oncol 1984; 20: 1221–25.

    Article  PubMed  CAS  Google Scholar 

  54. Gralla R, Raphael B, Golbey RB, Young CW. Phase 2 evaluation of vindesine in patients with nonsmall-cell carcinoma of the lung. Cancer Treat Rep 1979; 63: 1343–46.

    PubMed  CAS  Google Scholar 

  55. Bodey GP, Yap HY, Yap BS, Valdivieso M. Continuous infusion vindesine in solid tumors. Cancer Treat Rev 1980; 7 (suppl): 39–45.

    Article  PubMed  Google Scholar 

  56. Bodey GP, Valdivieso M, Bedikian AY, Yap BS, Freireich EJ. Vindesine in the therapy of solid tumors. In: Proc International Vinca Alkaloid Symposium–Vindesine. 1981; 84–91.

    Google Scholar 

  57. Dirks HP, Drings P, Manke HG, Vollhaber HH. Continuous vindesine infusion therapy in cases of advanced nonsmall-cell bronchogenic carcinoma. In: Proc International Vinca Alkaloid Symposium–Vindesine. 1981; 344–49.

    Google Scholar 

  58. Magill GB, Sordillo P, Gralla R, Golbey RB. Phase 2 trials of DVA, AMSA and DCNU as single agents in adult sarcomas. Proc Am Soc Clin Oncol 1980; 21: 362.

    Google Scholar 

  59. Popkin JD, Bromer RH, Vaughan CW, et al. Continuous vindesine infusion in advanced head and neck cancer. Am J Clin Oncol 1983; 6: 301–04.

    Article  PubMed  CAS  Google Scholar 

  60. Mayol XF, Beltran J, Rubio-Bazan R, Rifa J, Rosell Costa R, Lopez JJ. Multicenter phase 2 trial with 5-day continuous infusion of vindesine in metastatic malignant melanoma. Cancer Treat Rep 1984; 68: 1199–1200.

    PubMed  CAS  Google Scholar 

  61. Wagstaff J, Anderson HA, Shiu W, Thatcher N. Phase 2 study of vindesine infusion in visceral metastatic malignant melanoma. Cancer Treat Rep 1983; 67: 839–40.

    PubMed  CAS  Google Scholar 

  62. Bayssas M, Gonreia J, Ribaud P, et al. Phase 2 trial with vindesine for regression induction in patients with leukemias and hematosarcomas. Cancer Chemother Pharmacol 1979; 2: 247–55.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Mark J. Ratain M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas J. Vogelzang M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gerald P. Bodey M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Precept Press, Inc.

About this chapter

Cite this chapter

Ratain, M.J., Vogelzang, N.J., Bodey, G.P. (1987). Periwinkle Alkaloids I: Vinblastine and Vindesine. In: Cancer Chemotherapy by Infusion. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-3193-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-3193-0_13

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-7932-7

  • Online ISBN: 978-94-009-3193-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation